Dec272023Opdualag licensed for patients with advanced melanoma HM Government TwitterLinkedinFacebookemailThe Medicines and Healthcare products Regulatory Agency (MHRA) has today (27 December) approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of 12. Follow this news feed: